Reviewing Interleukin 17– and Interleukin 23–targeting Therapies and Best Practices in Psoriatic Disease Management Feat. Clinical Practice Video Vignettes
This continuing education activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVARTIS PHARMACEUTICALS CORPORATION.
Michael Crowe, PharmD, MBA, CSP, FMPA
Registered Manager of General Operations
Community, A Walgreens Pharmacy
Adjunct Assistant Professor of Clinical Pharmacy
Ferris State University College of Pharmacy
Big Rapids, Michigan
At the completion of this activity, the participant will be able to:
- Investigate the pathophysiology of psoriatic disease with a focus on the interleukin 17 and interleukin 23 pathways
- Explore the mechanism of action, safety, efficacy, and role in therapy for current and emerging interleukin 17 and interleukin 23 antagonist biologics for the treatment of psoriasis and/or psoriatic arthritis
- Determine best practices for specialty pharmacists in the management of psoriatic disease
TARGET AUDIENCE: Specialty pharmacists, specialty pharmacy directors/managers, health-system pharmacists, formulary decision makers, and other pharmacists involved in the care of patients with psoriatic disease
RELEASE DATE: March 16, 2020
EXPIRATION DATE: June 16, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.